A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Anti-IL17A Therapy for Venous Leg Ulcers
July 2023
in “
Journal of the European Academy of Dermatology and Venereology
”
Studysummary In a Phase II trial, Cox and colleagues reported that anti-IL17A therapy was well tolerated and led to a 64% reduction in wound size for venous leg ulcers unresponsive to standard treatments, although further validation in a larger trial is needed. Our plain-language summary of this paper — not a Tressless recommendation.
The document discusses several studies, including one on hair loss after COVID-19 infection. Michelini et al. examined four female patients experiencing Telogen Effluvium (TE) following SARS-CoV-2 infection, noting a decrease in hair density and dermal fibrosis. Histological analysis revealed features such as thickened nerve trunks and fibrosis, potentially linked to a cytokine storm activating various interleukins and tumor necrosis factor. The study highlights the need for further research to clarify the pathogenesis of COVID-19-related TE. Other topics covered include wound healing through IL17A therapy, long-term effects of botulinum toxin on gummy smiles, and a new treatment for chronic kidney disease-associated pruritus.
